FDA Appeal In Zocor Case Could Open The Door For More Generics In The Fall
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA filed a notice of appeal challenging a court decision granting Ivax and Ranbaxy 180-day exclusivity for generic simvastatin.
You may also be interested in...
Statin Prices Likely To Remain High After Zocor Exclusivity Win
Teva and Ranbaxy appear slated for 180 days of simvastatin exclusivity after federal court ruling postponing mass generic entry into the sector until 2007.
Astellas Plots US Portfolio Expansion
US president Mark Reisenauer talked to Scrip about the company's next growth drivers, including fezolinetant for vasomotor symptoms and zolbetuximab for gastric cancer.
Vir CEO George Scangos, Set To Retire, Reflects On A Long Career In Biotech
Bayer pharmaceuticals executive Marianne De Backer will succeed Scangos at Vir, tasked with advancing several mid-stage programs in areas like hepatitis B and influenza to late-stage development.